Reaktionsgleichung
[NH2:1][C:2]1[CH2:3][C:4]([C:14]([O:16][CH2:17][CH3:18])=[O:15])=[CH:5][C:6]2[CH:12]=[CH:11][C:10](Br)=[CH:9][C:7]=2[N:8]=1.[N:19]1[CH:24]=[C:23](B(O)O)[CH:22]=[N:21][CH:20]=1>>[NH2:1][C:2]1[CH2:3][C:4]([C:14]([O:16][CH2:17][CH3:18])=[O:15])=[CH:5][C:6]2[CH:12]=[CH:11][C:10]([C:23]3[CH:24]=[N:19][CH:20]=[N:21][CH:22]=3)=[CH:9][C:7]=2[N:8]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared by the procedure as described in Example 124 (Step F) using (1E,4E)-ethyl 2-amino-8-bromo-3H-benzo[b]azepine-4-carboxylate and pyrimidin-5-ylboronic acid. MS APCI (+) m/z 309 (M+1) detected; 1H-NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 9.02 (s, 2H), 7.84 (s, 1H), 7.54 (d, 1H), 7.47 (d, 1H), 7.30 (dd, 1H), 4.34 (q, 2H), 2.99 (s, 2H), 1.40 (t, 3H).
Quellen und Nachweise
- ORD-Eintrag
- ord-4376b8c38f0c44b2a8fab1eb30ab03ee
- Quelldatensatz
- uspto-grants-2016_01
- Patentnummer
- US09242964B2
Verknüpfte Notizen
Wird geladen…